

Dedicated to you

Financial Statements

Ceylon Hospitals PLC

For the 3rd Quarter ended 31st December 2022

Consolidated Statement of Profit or Loss and Other Comprehensive Income Accumulated Period of 09							riod of 09 Mont	hs
	Group Company			Gre	oup	Company		
	03 Months	03 Months	03 Months	03 Months	09 Months	09 Months	09 Months	09 Months
	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended
	31/12/2022	31/12/2021	31/12/2022	31/12/2021	31/12/2022	31/12/2021	31/12/2022	31/12/2021
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000
Revenue	2,174,592	1,834,290	1,200,065	1,212,531	5,754,409	5,814,828	3,196,506	3,902,302
Cost of Sales	(928,225)	(632,769)	(551,034)	(404,696)	(2,334,557)	(2,110,634)	(1,374,121)	(1,475,777)
Gross Profit	1,246,367	1,201,521	649,031	807,835	3,419,852	3,704,195	1,822,385	2,426,525
G1055 1 Tolit	1,240,307	1,201,321	042,031	607,633	3,417,032	3,704,193	1,022,303	2,420,323
Other Operating Income	14,910	19,235	11,975	10,736	50,575	43,716	35,964	27,045
Administrative Expenses	(747,147)	(648,754)	(444,318)	(429,650)	(2,035,387)	(2,158,958)	(1,268,080)	(1,534,024)
Other Operating Expenses	(334,585)	(197,079)	(153,869)	(111,061)	(735,208)	(531,473)	(365,765)	(337,092)
Results from Operating Activities	179,545	374,924	62,819	277,860	699,832	1,057,480	224,504	582,454
Finance Cost	(24,516)	(19,092)	(15,137)	(16,811)	(54,842)	(59,560)	(39,691)	(56,058)
Finance Income	72,451	20,401	79,151	1,802	202,916	55,387	320,576	248,496
Gain on Bargain Purchase	72,431	20,401	79,131	1,002	202,910	12,002	320,370	240,490
Share of Profit of an Equity Accounted Investee	_	_	_	_	_	13,263	_	_
Profit before Taxation	227,480	376,233	126,833	262,852	847,906	1,078,571	505,389	774,893
Tront before Taxation	227,400	370,233	120,033	202,032	047,700	1,070,371	303,307	774,073
Taxation	(142,941)	(55,320)	(93,849)	(28,863)	(266,584)	(233,876)	(120,725)	(117,519)
Net Profit after Taxation	84,539	320,913	32,984	233,988	581,322	844,695	384,664	657,374
Other Comprehensive Income								
Items will not be reclassified to profit or loss								
Net Change in Fair Value on Equity Investments at								
FVTOCI	3,115	2,104	6,330	2,104	5,157	2,168	6,358	2,168
Deferred Tax on Revaluation Surplus	(283,571)	2,101	(283,571)	2,101	(283,571)	2,100	(283,571)	2,100
Other Comprehensive Income for the period	(280,456)	2,104	(277,241)	2,104	(278,414)	2,168	(277,213)	2,168
Total Comprehensive Income for the period	(195,917)	323,017	(244,257)	236,092	302,908	846,863	107,451	659,542
r	(1,0,0,1,1)	525,617	(=11,207)	200,002	002,500	0.10,000	207,102	007,0.2
Profit Attributable to:								
Equity Holders of the Parent	85,569	318,852	32,984	233,988	521,015	756,831	384,664	657,374
Non-Controlling Interest	(1,030)	2,061	•	-	60,307	87,864	•	-
	84,539	320,913	32,984	233,988	581,322	844,695	384,664	657,374
Total Comprehensive Income Attributable to:								
Equity Holders of the Parent	(194,281)	320,956	(244,257)	236,092	242,828	758,999	107,451	659,542
Non-Controlling Interest	(1,636)	2,061	-	-	60,080	87,864	-	
	(195,917)	323,017	(244,257)	236,092	302,908	846,863	107,451	659,542
Earnings per Share - Basic	2.53	9.41	0.97	6.91	15.38	22.34	11.36	19.41
	•						·	

The above figures are provisional and subject to audit.

Consolidated Statement of Financial Position

GROUP	COMPANY		GROUP		COMP	ANY
Audited	Audited		Unaudited	Unaudited	Unaudited	Unaudited
As at	As at		As at	As at	As at	As at
31/03/2022	31/03/2022		31/12/2022	31/12/2021	31/12/2022	31/12/2021
Rs. '000	Rs. '000		Rs. '000	Rs. '000	Rs. '000	Rs. '000
		ASSETS				
		Non-Current Assets				
8,481,203	5,592,128	Property, Plant and Equipment	9,753,828	8,190,051	6,699,899	5,417,958
288,954	288,954	Right of Use Assets	289,163	293,283	285,662	293,283
-	1,457,821	Investments in Subsidiary	-	-	1,457,821	1,457,821
272,923	71,416	Other Financial Assets	307,697	343,835	80,439	71,267
890	-	Prepaid Rent		579	-	-
9,043,970	7,410,319	_	10,350,688	8,827,748	8,523,821	7,240,329
		Commont Aggets				
835,149	603 571	Current Assets Inventories	985,534	679,882	786,164	553,293
306,454	,	Trade and Other Receivables	354,018	331,578	188,794	180,385
252,441		Prepayments	816,796	240,561	563,880	179,841
1,934		Amount Due from Related Parties	10,553	4,036	49,208	111,931
1,451,388		Other Financial Assets	843,175	958,820	66,532	149,524
13,278	,	Tax Refund Due	13,259	956,620	13,259	147,524
898,189		Cash and Cash Equivalents	384,111	772,382	230,238	129,181
3,758,833	1,981,341	- Cash and Cash Equivalents	3,407,446	2,987,258	1,898,075	1,304,155
12,802,803		Total Assets	13,758,134	11,815,006	10,421,896	8,544,484
12,002,000	>,5>1,000	=	10,700,101	11,010,000	10,121,000	5,5 , . 5 .
		EQUITY AND LIABILITIES				
		Equity Attributable to Equity holders of the parent				
916,366	916,366	Stated Capital	916,366	916,366	916,366	916,366
2,691,662		Revaluation Reserve	2,408,091	2,691,662	1,850,973	2,134,544
65,868		Fair Value Reserve	71,252	70,604	6,958	2,296
3,873,950		Revenue Reserves	4,225,601	3,599,877	2,910,736	2,535,381
7,547,846	5,746,946		7,621,310	7,278,509	5,685,033	5,588,587
734,254	-	Non-Controlling Interests	711,004	693,439	, , , <u>-</u>	-
8,282,100	5,746,946	Total Equity	8,332,314	7,971,948	5,685,033	5,588,587
		Non-Current Liabilities				
1,701,501		Interest Bearing Loans and Borrowings	2,020,564	1,043,665	1,871,676	936,891
-		Deferred Revenue	-	-	27,442	32,254
177,998		Retirement Benefit Obligations	185,488	243,888	164,207	218,177
707,793		_Deferred Tax Liabilities	1,078,076	652,562	808,623	440,809
2,587,292	2,247,106	=	3,284,128	1,940,116	2,871,948	1,628,131
		Current Liabilities				
246,765		Bank Overdraft	312,550	181,775	217,252	92,213
306,060		Interest Bearing Loans and Borrowings	333,893	336,426	248,830	279,255
1,247,893		Trade and Other Payables	1,337,306	1,243,629	884,680	796,223
127,894		Taxation Payable	105,550	129,049	19,372	66,615
4,799		_Amount Due to Related Parties	52,393	12,064	494,781	93,460
1,933,411	1,397,608	_	2,141,692	1,902,942	1,864,915	1,327,765
12,802,803	9,391,660	Total Equity and Liabilities	13,758,134	11,815,006	10,421,896	8,544,484

The above figures are provisional and subject to audit.

Sgd

Thusitha Rubasinghe

Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these Financial Statements. Signed for and on behalf of the Board by,

Sgd **A E Tudawe** Chairman Sgd U D Tudawe Director

CEYLON HOSPITALS PLC Consolidated Statement of Changes in Equity

Group		Attributable	1				
- <u>'</u>	Stated	Revaluation	Fair Value	Revenue	Total	Non-Controlling	Total
	Capital	Reserve	Reserve	Reserves		Interests	Equity
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000
Balance as at 31st March 2021	916,366	2,691,662	68,436	2,951,439	6,627,903	592,626	7,220,529
Net Profit for the Year	-	-	-	982,324	982,324	127,202	1,109,526
Other Comprehensive Income							
Actuarial Gain on Gratuity Valuation	-	-	-	55,965	55,965	300	56,265
Deferred Tax effect on Gratuity Valuation	-	-	-	(6,342)	(6,342)	332	(6,010)
Prior Year Adjustments - Inventory Written-off	-	-	-	(989)	(989)	(230)	(1,219)
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(2,568)	-	(2,568)	217	(2,351)
Share Buyback	-	-	-	(54)	(54)	-	(54)
Total Comprehensive Income for the Year	-	-	(2,568)	1,030,904	1,028,335	127,822	1,156,158
Transactions with Owners in their capacity as Owners							
Non-Controlling Interest on Acquisition of Subsidiary	-	-	-	-	-	127,301	127,301
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)	(113,495)	(221,888)
	-	-	-	(108,393)	(108,393)	13,806	(94,587)
Balance as at 31st March 2022	916,366	2,691,662	65,868	3,873,950	7,547,845	734,254	8,282,100
Net Profit for the Nine months ended 31 December 2022	-	-	-	521,015	521,015	60,307	581,322
Other Comprehensive Income							
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	5,384	-	5,384	(227)	5,157
Deferred Tax Effect on Revaluation Surplus	-	(283,571)	-	-	(283,571)	-	(283,571)
Total Comprehensive Income for the Nine Months Ended 31 December 2022	-	(283,571)	5,384	521,015	242,828	60,080	302,908
Transactions with Owners in their capacity as Owners							
Shares issued at Rights Issue by subsidiary	-	-	-	-	-	5,860	5,860
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)	(89,190)	(258,554)
	-	-	-	(169,364)	(169,364)	(83,330)	(252,694)
Balance as at 31st December 2022	916,366	2,408,091	71,252	4,225,601	7,621,310	711,004	8,332,314

Company

	Stated Capital	Revaluation Reserve	Fair Value Reserve	Revenue Reserves	Total
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000
Balance as at 31st March 2021	916,366	2,134,544	128	1,986,400	5,037,438
Net Profit for the Year	-	-	-	770,550	770,550
Other Comprehensive Income					
Actuarial Gain on Gratuity Valuation	-	-	-	54,510	54,510
Deferred Tax Effect on Gratuity Valuation	-	-	-	(7,631)	(7,631)
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	472	-	472
Total Comprehensive Income for the Year	=	-	472	817,429	817,901
Transactions with Owners in their capacity as Owners					
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)
	-	-	-	(108,393)	(108,393)
Balance as at 31st March 2022	916,366	2,134,544	600	2,695,436	5,746,946
Net Profit for the Nine months ended 31 December 2022	-	-	-	384,664	384,664
Other Comprehensive Income					
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	6,358	-	6,358
Deferred Tax Effect on Revaluation Surplus	-	(283,571)	-	-	(283,571)
Total Comprehensive Income for the Nine Months ended 31 December 2022	-	(283,571)	6,358	384,664	107,451
Transactions with Owners in their capacity as Owners					
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)
	-	-	-	(169,364)	(169,364)
Balance as at 31st December 2022	916,366	1,850,973	6,958	2,910,736	5,685,033

Group		Attributable	to equity holders	s of the parent			
	Stated	Revaluation	Fair Value	Revenue	Total	Non Controlling	Total
	Capital	Reserve	Reserve	Reserves		Interests	Equity
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000
Balance as at 31st March 2020	916,366	2,483,785	65,922	2,439,753	5,905,826	587,760	6,493,586
Net Profit for the Year	-	-	-	560,349	560,349	39,910	600,259
Other Comprehensive Income							
Deferred Tax Effect on Revaluation Gain	-	207,877	-	-	207,877	752	208,629
Actuarial Gain on Gratuity valuation	-	-	-	32,865	32,865	370	33,235
Deferred Tax Effect on Gratuity valuation	-	-	-	(7,007)	(7,007)	(610)	(7,617)
Net Change in Fair Value on Equity Investments at FVTOCI		-	2,514	-	2,514	554	3,068
Total Comprehensive Income for the Year	-	207,877	2,514	586,206	796,597	40,975	837,572
Transactions with Owners in their capacity as Owners							
Share of additional capital attributable to NCI	-	-	-	-	-	1,750	1,750
Dividend Paid - Ordinary Shares		-	-	(74,520)	(74,520)	(37,859)	(112,379)
	-	-	-	(74,520)	(74,520)	(36,109)	(110,629)
Balance as at 31st March 2021	916,366	2,691,662	68,436	2,951,439	6,627,903	592,626	7,220,530
Net Profit for the nine months ended 31 December 2021	-	-	-	756,831	756,831	87,864	844,695
Other Comprehensive Income							
Net Change in Fair Value on Equity Investments at FVTOCI	_	_	2,168	-	2,168	-	2,168
Total Comprehensive Income for the Nine months ended 31 December 2021	-	-	2,168	756,831	758,999	87,864	846,863
Transactions with Owners in their capacity as Owners							
Non-Controlling Interest on Acquisition of Subsidiary	_	_	_	_	-	126,444	126,444
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)	(113,496)	(221,888)
•			-	(108,393)	(108,393)	12,948	(95,444)
Balance as at 31st December 2021	916,366	2,691,662	70,604	3,599,877	7,278,509	693,439	7,971,948
	. 10,000	=,571,002	70,001	-,->>,0	.,=,0,00	0,0,10,	. ,

Company

	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000
Balance as at 31st March 2020	916,366	1,931,063	-	1,588,064	4,435,493
Net Profit for the Year	-	-	-	446,118	446,118
Other Comprehensive Income					
Deferred Tax Effect on Revaluation Gain	-	203,481	-	-	203,481
Actuarial Gain on Gratuity valuation	-	-	-	31,090	31,090
Deferred Tax Effect on Gratuity valuation	-	-	-	(4,353)	(4,353)
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	128	-	128
Total Comprehensive Income for the Year	-	203,481	128	472,855	676,464
Transactions with Owners in their capacity as Owners					
Dividend Paid - Ordinary Shares	-	-	-	(74,520)	(74,520)
	-	-	-	(74,520)	(74,520)
Balance as at 31st March 2021	916,366	2,134,544	128	1,986,400	5,037,438
Net Profit for the nine months ended 31 December 2021	-	-	-	657,374	657,374
Other Comprehensive Income					
Net Change in Fair Value on Equity Investments at FVTOCI	_	-	2,168	-	2,168
Total Comprehensive Income for the Nine months ended 31 December 2021	-	-	2,168	657,374	659,542
Transactions with Owners in their capacity as Owners					
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)
·	-	-	-	(108,393)	(108,393)
Balance as at 31st December 2021	916,366	2,134,544	2,296	2,535,381	5,588,587

Consolidated Statement of Cash Flows

Group	Company		Gro	un	Comp	anv
Audited	Audited		Unaudited	Unaudited	Unaudited	Unaudited
12 Months	12 Months		09 Months	09 Months	09 Months	9 Months
Ended	Ended		Ended	Ended	Ended	Ended
31/03/2022	31/03/2022		31/12/2022	31/12/2021	31/12/2022	31/12/2021
Rs '000	Rs '000		Rs '000	Rs '000	Rs '000	Rs '000
Ks 000	Ks 000	Cash Flows from/ (Used in) Operating Activities	KS 000	K3 000	KS 000	K3 000
1,388,911	902 276	Net Profit Before Income Tax Expenses	847,906	1,078,571	505,389	774,893
1,300,911	902,270	Net From Before income Tax Expenses	047,900	1,076,371	303,309	114,693
		Adjustments for :				
25,388	21 790	Inventory Write-off/(Write in)	547	23,533	(1,763)	18,732
19,490		Bad Debts Write-off	548	1,114	794	1,101
339,848	,	Depreciation Charge	282,133	248,770	154,952	136,687
108,031		Amortisation of Right to use assets	86,103	79,201	86,103	79,201
(81,822)		Finance Income	(202,916)	(55,387)	(320,576)	(248,496)
80,567		Finance Cost	54,842	59,560	39,691	56,058
100		Amortisation of Deferred Rent Expenses/(Income)	(2,610)	411	(4,028)	(1,007)
(5,202)		(Profit)/ Loss on Disposal of Property, Plant and Equipment	(2,010)	-	(4,026)	(1,007)
(32,917)		Fair value (Gain)/Loss on Financial Instruments	11,091	3,659	(3,322)	2,168
(32,917)	-	Foreign Exchange (Gain)/Loss	(16,853)	3,039	(8,988)	2,106
_	-	Reversal of provisions	(88,500)	-	(88,500)	-
(11,724)	-	Share of Profit of an Equity Accounted Investee	(88,500)	(13,263)	(88,500)	-
28,948	25.080	Provision for Defined Benefit Plans	29,250	29,390	24,300	24,300
1,859,618		Operating Profit before Working Capital Changes	1,001,541	1,455,559	384,052	843,636
1,039,010	1,003,270	Operating Front before working Capital Changes	1,001,541	1,455,559	304,032	643,030
(324,660)	(264 887)	(Increase)/Decrease in Inventories	(150,932)	(167,538)	(90,829)	(121,551)
(184,978)		(Increase)/Decrease in Trade and Other Receivables	(595,614)	(179,847)	(334,472)	(82,923)
576,763		Increase//Decrease in Trade and Other Payables	177,913	572,499	110,731	411,507
(171,712)		(Increase)/Decrease Related Party Dues	38,976	(166,549)	402,971	(112,429)
1,755,031			471,884	1,514,126	472,453	
1,733,031	1,085,130	Cash Generated from Operations	4/1,004	1,314,120	472,455	938,240
(51,361)	(41.581)	Finance Cost Paid	(54,842)	(49,029)	(39,691)	(45,527)
(37,567)		Defined Benefit Plan Costs Paid	(21,760)	(28,383)	(16,883)	(23,201)
(160,869)		Income Tax Paid	(202,199)	(150,150)	(102,182)	(92,798)
1,505,234		Net Cash from Operating Activities	193,083	1,286,563	313,697	776,715
1,303,234	901,202	Net Cash from Operating Activities	193,063	1,200,303	313,097	770,713
		Cash Flows from/ (used in) Investing Activities				
(1,109,961)	(607 335)	Acquisition of Property, Plant and Equipment	(1,554,759)	(726,223)	(1,262,723)	(473,028)
(1,10),)01)	(077,333)	Acquisition of Property, Frank and Equipment Acquisition of Right to use assets	(1,554,757)	(720,223)	(1,202,723)	(473,020)
8,750	8 750	Proceeds from Sale of Property, Plant and Equipment	_	2,040	_	1,750
(422,851)		(Acquisition)/ Disposal of other Investments	567,506	90,605	593,411	(30,705)
81,822		Income from Investments	202,916	55,387	320,576	248,496
(1,442,240)	, -	Net Cash Flows from/ (used in) Investing Activities	(784,337)	(578,191)	(348,736)	(253,487)
(1,442,240)	(975,988)	- Net Cash Flows from (used in) livesting Activities	(704,337)	(376,191)	(346,730)	(233,467)
		Cash Flows from/ (used in) Financing Activities				
1,019,153	900 909	Receipts from Interest Bearing Loans and Borrowings	500,000	318,329	375,000	200,909
(740,022)		Re-payments to Interest Bearing Loans and Borrowing	(155,690)	(658,918)	(112,155)	(630,983)
(135,537)		Lease Rent Payment	(80,224)	(100,110)	(80,224)	(100,110)
(54)	(133,337)	Share buy back	(00,224)	(100,110)	(00,224)	(100,110)
248,399	_	Non-Controlling Interest on Acquisition of Subsidiary	_	126,444	_	_
240,399	-	Proceeds on Shares issued at Rights Issue	5,860	120,444	-	-
(221,888)	(108 303)	Dividends Paid	(258,554)	(221,888)	(169,364)	(108,393)
170,051		Net Cash Flows from/ (used in) Financing Activities	11,392	(536,143)	13,257	(638,577)
170,031	(42,023)	- Not Cash I lows from (used in) I maneing Activities	- 11,372	(330,143)	-	(030,377)
233,044	(117 549)	Net Increase/ (Decrease) in Cash and Cash Equivalents	(579,862)	172,228	(21,782)	(115,349)
418,379		Cash and Cash Equivalents at the Beginning of the Year	651,423	418,379	34,768	152,317
651,423		Cash and Cash Equivalents at the End of the Year	71,561	590,607	12,986	36,967
051,425	J-7, / UO	•		370,007	12,700	30,707
(046760)	(04.507)	Analysis of Cash and Cash Equivalents	(212.550)	(101 775)	(215 252)	(02.212)
(246,766)		Bank Overdraft	(312,550)	(181,775)	(217,252)	(92,213)
898,189		Cash in Hand and at Bank	384,111	772,382	230,238	129,181
651,423	34,768	=	71,561	590,607	12,986	36,967

Explanatory Notes

01. CORPORATE INFORMATION

Ceylon Hospitals PLC is a public limited company incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. Ordinary shares of the company are listed on the Colombo Stock Exchange.

02. INTERIM CONDENSED FINANCIAL STATEMENTS

The financial statements for the nine months ended 31 December 2022, includes "the Company" referring to Ceylon Hospitals PLC, as the holding company and "the Group" referring to the companies whose accounts have been consolidated therein.

03. APPROVAL OF FINANCIAL STATEMENTS

The interim condensed financial statements of the Group and the Company for the Nine months ended 31 December 2022 were authorised for issue by the Board of Directors on 13th February 2023.

04. BASIS OF PREPARATION AND CHANGES TO ACCOUNTING POLICIES

4.1 Basis of preparation

The interim financial statements for the nine months ended 31 December 2022 have been prepared in accordance with LKAS 34 Interim Financial Reporting.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 March 2022.

4.2 Fair value measurement and related fair value disclosures

The fair values of all the financial assets and financial liabilities recognised during the quarter were not materially different from the transaction prices at the date of initial recognition. There were no transfers between Level 1 and Level 2 and no transfers into or out of Level 3 categories as per the fair value hierarchy, during the quarter. The fair value changes on financial instruments in Level 3 category was properly recorded in the statement of other comprehensive income and there were no purchases and/or disposals during the period.

Fair valuation was done as of 31 December 2022 for all unquoted equity shares classified as Level 3 within the fair value hierarchy according to fair valuation methodology. Fair value would not significantly vary if one or more of the inputs were changed.

05. Capital Commitments

The Project 2022 undertaken in FY 2018/19 is now nearing completion and the total construction cost is expected to be Rs. 2.347 Bn excluding VAT. The Main Constructor for the Project 2022 is M/s Tudawe Brothers (Pvt) Ltd that is a Related Party to the Company.

06. There were no contingent liabilities as at the Balance Sheet date which would require adjustment or disclosure in the Financial Statements.

07. Events occuring after the Balance Sheet date

The Company has planned for a Rights Issue and this is to take place in early March 2023. The purpose of the Rights Issue is to raise capital to part finance Project-2022 and the proceeds expected from the issue is aproximately Rs. 226 Mn.

- 08. Related party transactions for the quarter ended 31 December 2022 were reviewed by the Related Party Transactions Review Committee and it was decided there were no transactions requiring Board Approval, immediate CSE disclosure or Shareholder approval.
- 09. Amrak Institute of Medical Sciences (Pvt) Ltd which is a Sub-Subsidiary of Ceylon Hospital PLC issued 1,586,000 ordinary shares for Rs. 15,860,000/- at Rights Issue on 01 August 2022.
- 10 The recent amendments to The Inland Revenue Act No. 45 of 2022, w.e.f 1st October 2022 for corporate income tax, increased tax charge out rate to 30% from previous concessinory rate applicable to healthcare at 14%. However, Durdans Medical and Surgical Hospital (Pvt) Ltd that will continue at a tax rate of 15% being a BOI approved entity.

Accordingly the income tax charge for the period was substantially increased due to the impact of the same on Deferred Tax.

Related Party Transactions

For the Nine Months ended 31 December 2022 - In Rs. '000

For the Nine Months ended 31 December 2022 - In Rs. '000			1	T
Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions
Durdon Management Constructed	Illian de Demont	Management (as	D	22.901
Durdans Management Services Ltd	Ultimate Parent	Management fee Rendering of utilities and other cost	Recurrent Recurrent	33,801 1,017
		Total		34,818
Donald and Medical and Constitution (to 1/Dec) 1 (d	Colori dia	Calan of Downson and assessment land	D	20,000
Durdans Medical and Surgical Hospital (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables	Recurrent	28,000
		Rendering of medical services	Recurrent	375,388
		Sharing of utilities and other cost	Recurrent	430,520
		Purchases of Drugs and consumables	Recurrent	31,214
		Receiving of medical services	Recurrent	135,351
		Receiving of utilities and other cost	Recurrent	87,594
		Total		1,088,067
Durdans Heart Centre (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables	Recurrent	3,545
		Rendering of medical services	Recurrent	83,218
		Sharing of utilities and other cost	Recurrent	96,248
		Purchases of Drugs and consumables	Recurrent	10,844
		Receiving of medical services	Recurrent	38,230
		Sharing of utilities and other cost	Recurrent	448
		Total		232,533
Amrak Institute of Medical Sciences (Pvt) Ltd	Subsidiary	Rendering of utilities and other cost	Recurrent	2,379
		Total		2,379
		Sale of Drugs and consumables	Recurrent	652
Ceygen Biotech (Pvt) Ltd	Subsidiary	Receiving of utilities and other cost	Recurrent	23
	Subsidiary	Total	Recuirent	675
		Total		073
	Affiliate	Sale of Drugs and consumables	Recurrent	1,823
Commercial Marketing Distributors (Pvt) Ltd	Aiimate	Purchases of Drugs and consumables	Recurrent	143,954
		Total	Recurrent	145,777
		Total		145,///
Tradevice Prothesis (Dest) Ltd	Affiliate	Dandouing of modical	Dog	101
Tudawe Brothers (Pvt) Ltd	Aimate	Rendering of medical services	Recurrent	121 121
		Total		121
				Aggregate Value of
Name of the Related Party	Relationship	Transactions	Nature	Related Party
				Transactions
Tudawe Brothers (Pvt) Ltd	Affiliate	Project 2022 Construction Cost	Non Recurrent	354,741
		Total		354,741

CEYLON HOSPITALS PLC

Share Information

Number of Shares Represented in Stated Capital

 Voting Shares
 25,527,272

 Non-Voting Shares
 8,345,454

 Total
 33,872,726

Public Shareholding as at 31st December 2022

r ubile Shareholding as at 51st December 2022		
	Voting	Non-Voting
Number of shareholders	2,308	1,260
Number of shares	5,657,963	4,221,339
Holding Percentage	22.16%	50.58%
Float Adjusted Market Capitalisation (Rs Mn)	820	
Float Adjusted Market Capitalisation Option	Less than 2.5 B	Sn (Option 5)

Directors' and Chief Executive Officer's Shareholding as at 31st December 2022

	Number of Snares		
	Voting	Non-Voting	
Mr. A. E. Tudawe	215,202	-	
Mr. U. D. Tudawe	170,616	-	
Dr A. D. P. A. Wijegoonewardene	220,582	-	
Mr. Y. N. R. Piyasena	501,000	-	
Mr. A. S. Abeyewardene	1,440	1,200	
Mr. A. D. B. Talwatte	1,000	-	
Mr. A.V.R. De Silva Jayatilleke	100	-	
Mr. A.S. Tudawe	48	1,000	

Market Prices recorded during the Quarter

warker i nees recorded during the Quarter								
	Highest Traded Price		Lov	Lowest Traded Price		Last		
			Trade			ed Price		
	2022/23	2021/22	2022/23	2021/22	2022/23	2021/22		
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.		
Voting	160.00	152.00	130.00	119.50	145.00	151.00		
_	21/11/2022	31/12/2021	05/10/2022	01/10/2021	28/12/2022	31/12/2021		
Non - Voting	126.00	130.00	103.25	103.00	110.00	123.50		
	11/11/2022	27/12/2021	05/10/2022	18/10/2021	28/12/2022	31/12/2021		

Per Share Ratios

rei Share Katios					
	Gre	Group		npany	
	As at	As at	As at	As at	
	31/12/2022	31/12/2021	31/12/2022	31/12/2021	
	Rs.	Rs.	Rs.	Rs.	
Earnings Per Share	15.38	22.34	11.36	19.41	
Net Asset Per Share	225.00	214.88	167.84	164.99	

CEYLON HOSPITALS PLC

Top 20 Shareholders Listed as at 31 December 2022

Voting Shareholders

Name of the Shareholder	Country of Residence	Number of Shares	Holding %
Durdans Management Services Ltd	Sri Lanka	17,471,382	68.44
Lawrance Tudawe Management Services (Pvt) Ltd	do	600,077	2.35
Mr. Y. N. R. Piyasena	do	501,000	1.96
Mr. Deen Mohamed Fazal Aslam	do	474,500	1.86
Galle Face Capital Partners PLC	do	400,000	1.57
Mr. Merill J. Fernando	do	367,530	1.44
Cargo Boat Development Company PLC	do	305,485	1.20
Mr. D.G. Wijemanna	do	299,034	1.17
MJF Holdings Ltd	do	270,981	1.06
Mr.R.P. Weerasooriya	do	244,849	0.96
Dr. A. D. P. A. Wijegoonewardene	do	220,582	0.86
Mr. A. E. Tudawe	do	215,202	0.84
Mrs. H. K. Weerasinghe	do	200,000	0.78
Mrs. L. I. Weerasinghe	do	200,000	0.78
Miss. T. T. Weerasinghe	do	200,000	0.78
Mr. U. D. Tudawe	do	170,616	0.67
Mr. H. L. Tudawe	do	165,114	0.65
Mr. A. D. Tudawe	do	161,984	0.63
Mr. P.V. Tudawe	do	156,978	0.61
Mr. A. H. Munasinghe	do	86,326	0.34
		22,711,640	88.97

Non-Voting Shareholders

Non-voting Shareholders			
Name of the Shareholder	Country of Residence	Number of Shares	Holding %
Durdans Management Services Ltd	Sri Lanka	2,726,540	32.67
Employees' Provident Fund	do	1,154,371	13.83
MJF Holdings Ltd	do	598,646	7.17
E W Balasuriya & Co. (Pvt) Ltd	do	330,619	3.96
Mr. D. Ratnayake	do	146,866	1.76
Mr. A. H. Munasinghe	do	138,614	1.66
Tudawe Engineering Services (Pvt) Ltd	do	91,986	1.10
Mr. D. A. Cabraal	do	82,500	0.99
Mr. S. S. Sithambaranathan	do	77,753	0.93
Mr. A. D. Tudawe	do	71,151	0.85
Mr. P. S. De Mel	do	70,822	0.85
Ms. T. T. Weerasinghe	do	68,485	0.82
Commercial Bank of Ceylon PLC A/C No. 04	do	61,100	0.73
Peoples Leasing & Finance PLC /Mr. P. A. I. S. Perera	do	60,000	0.72
Mr. D.P. L. De Mel	do	58,908	0.71
Saman Villas Limited	do	58,462	0.70
Mr. H. A. Cabraal	do	50,000	0.60
Mr. G. D. M. Ranasinghe	do	50,000	0.60
Mr. U. D. Wickremesooriya	do	50,000	0.60
Hallsville Trading Group INC	do	49,123	0.59
	•	5,995,946	71.85

CEYLON HOSPITALS PLC

CORPORATE INFORMATION

Name of Company

Ceylon Hospitals PLC

Brand Name

DURDANS

Legal Form

A quoted public company with limited liability incorporated in Sri Lanka under the Companies Ordinance No.51 of 1938 and registered under the Companies Act No.07 of 2007.

Company Registration Number

PQ 113

Stocks Exchange Listing

The Ordinary Shares of the Company are listed on the Colombo Stock Exchange of Sri Lanka.

Registered Office

No.03, Alfred Place, Colombo 03.

Bankers

Bank of Ceylon
Commercial Bank of Ceylon PLC
DFCC Bank PLC
Hatton National Bank PLC
National Development Bank PLC
Nations Trust Bank PLC
Sampath Bank PLC
Seylan Bank PLC
Union Bank of Colombo PLC
People's Bank

Auditors

Messers.B.R.De.Silva & Co. Chartered Accountants No. 22/4,Vijaya Kumaratunga Mawatha Colombo 05.

Lawyers

Mr. D.F.R. Jayamaha Hector Jayamaha Law Office, No.228,Thimbirigasyaya Road, Colombo 05.

Secretaries

Nexia Corporate Consultants (Pvt) Ltd No. 181, Nawala Road, Narahenpita.

Registrars

S S P Corporate Services (Pvt) Ltd 546, Galle Road, Colombo 03.